BLUE bluebird bio Inc
Price (delayed)
$4.12
Market cap
$40.34M
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$24.84
Enterprise value
$332.9M
bluebird bio, Inc., based in Cambridge, Massachusetts, is a biotechnology company that develops gene therapies for severe genetic disorders and cancer. The company's only - in the European Union -
Highlights
The revenue has surged by 184% year-on-year and by 58% since the previous quarter
The gross margin has soared by 86% from the previous quarter and by 52% YoY
The gross profit has soared by 78% from the previous quarter but it has contracted by 38% YoY
The company's net income rose by 18% QoQ but it fell by 14% YoY
bluebird bio's equity has plunged by 116% YoY
The quick ratio has plunged by 80% YoY and by 17% from the previous quarter
Key stats
What are the main financial stats of BLUE
Market
Valuations
Earnings
Shares outstanding
9.79M
Market cap
$40.34M
Enterprise value
$332.9M
Price to earnings (P/E)
N/A
Price to book (P/B)
N/A
Price to sales (P/S)
0.48
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
3.97
Revenue
$83.81M
Gross profit
-$5.57M
Operating income
-$270.46M
Net income
-$240.72M
EBIT
-$218.07M
EBITDA
-$132.59M
Free cash flow
-$262.62M
Per share
Balance sheet
Liquidity
EPS
-$24.84
EPS diluted
-$24.84
Free cash flow per share
-$27.1
Book value per share
-$3.24
Revenue per share
$8.65
TBVPS
$45.93
Total assets
$460.23M
Total liabilities
$491.77M
Debt
$354.87M
Equity
-$31.53M
Working capital
-$166.79M
Debt to equity
-11.25
Current ratio
0.48
Quick ratio
0.25
Net debt/EBITDA
-2.21
Margins
Efficiency
Dividend
EBITDA margin
-158.2%
Gross margin
-6.6%
Net margin
-287.2%
Operating margin
-322.7%
Return on assets
-45.8%
Return on equity
-656.3%
Return on invested capital
-46.7%
Return on capital employed
-157.1%
Return on sales
-260.2%
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
BLUE stock price
How has the bluebird bio stock price performed over time
Intraday
-1.67%
1 week
-5.07%
1 month
0.98%
1 year
-77.69%
YTD
-50.6%
QTD
-15.57%
Financial performance
How have bluebird bio's revenue and profit performed over time
Revenue
$83.81M
Gross profit
-$5.57M
Operating income
-$270.46M
Net income
-$240.72M
Gross margin
-6.6%
Net margin
-287.2%
The revenue has surged by 184% year-on-year and by 58% since the previous quarter
The gross margin has soared by 86% from the previous quarter and by 52% YoY
The gross profit has soared by 78% from the previous quarter but it has contracted by 38% YoY
BLUE's operating margin has surged by 61% year-on-year and by 47% since the previous quarter
Growth
What is bluebird bio's growth rate over time
Valuation
What is bluebird bio stock price valuation
P/E
N/A
P/B
N/A
P/S
0.48
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
3.97
The EPS has increased by 36% year-on-year and by 31% since the previous quarter
bluebird bio's equity has plunged by 116% YoY
The revenue has surged by 184% year-on-year and by 58% since the previous quarter
BLUE's P/S is 83% below its last 4 quarters average of 2.9
Efficiency
How efficient is bluebird bio business performance
bluebird bio's ROE has plunged by 109% from the previous quarter
The return on sales has surged by 61% year-on-year and by 49% since the previous quarter
bluebird bio's ROA has decreased by 40% YoY but it has increased by 12% from the previous quarter
bluebird bio's return on invested capital has decreased by 40% YoY but it has increased by 16% QoQ
Dividends
What is BLUE's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for BLUE.
Financial health
How did bluebird bio financials performed over time
The total assets is 6% smaller than the total liabilities
The quick ratio has plunged by 80% YoY and by 17% from the previous quarter
The current ratio has plunged by 66% YoY and by 6% from the previous quarter
bluebird bio's equity has plunged by 116% YoY
BLUE's debt to equity has surged by 82% since the previous quarter
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise
specified. Data from 
and Sharadar.